Pyxis Oncology, Inc.
PYXSNASDAQHealthcare● Active
$1.69
$-0.09(-5.06%)
Market Cap$107070761
P/E Ratio—
52W High$5.55
52W Low$0.97
Pyxis Oncology, Inc. (PYXS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PYXS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $13.86M | $16.15M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $2.39M | $0.47M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $11.47M | $15.67M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 82.77% | 97.06% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $73.70M | $58.75M | $49.59M | $86.13M | $51.05M |
| G&A Expenses | $22.19M | $25.42M | $32.61M | $37.35M | $18.66M |
| Total Operating Expenses | $95.89M | $105.13M | $82.20M | $123.48M | $69.72M |
| Operating Income | ($84.42M) | ($89.46M) | ($82.20M) | ($123.48M) | ($69.72M) |
| Operating Margin %(computed) | -609.18% | -554.07% | — | — | — |
| Interest Income | $3.61M | $7.04M | $6.63M | $2.76M | $0.02M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($78.23M) | ($79.50M) | ($73.79M) | ($120.72M) | ($75.97M) |
| Income Tax Expense | $1.39M | ($2.16M) | $0.00M | $0.00M | $0.00M |
| Net Income | ($79.62M) | ($77.33M) | ($73.79M) | ($120.72M) | ($75.97M) |
| Net Margin %(computed) | -574.55% | -478.95% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.28 | $-1.32 | $-1.85 | $-3.57 | $-2.53 |
| Wtd Avg Shares | 62.14M | 58.45M | 39.90M | 33.03M | 32.22M |
| EBITDA | ($79.91M) | ($65.51M) | ($80.27M) | ($122.77M) | ($69.07M) |
| EBITDA Margin %(computed) | -576.63% | -405.76% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Pyxis Oncology, Inc. data
About Pyxis Oncology, Inc. (PYXS) Income Statement
Pyxis Oncology, Inc. (PYXS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PYXS reported revenue of $0.01B, gross profit of $0.01B (gross margin 82.77%), and net income of ($0.08B) — a net profit margin of -574.55%.
Frequently asked questions
PYXS · 4 questionsPyxis Oncology, Inc. (PYXS) reported revenue of $0.01B for 2025, down 14.2% year-over-year.
PYXS revenuePYXS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08